A Phase 1a/1b Study of CXCR4 Peptide Antagonist (LY2510924) Administered in Combination With the Anti-PD-L1 Antibody, Durvalumab (MEDI4736), in Advanced Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Durvalumab (Primary) ; LY 2510924 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 13 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 18 Aug 2017 Planned End Date changed from 1 Aug 2018 to 1 Nov 2017.
- 18 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Nov 2017.